News

New Insights on Penetrium's Role in Combating TNBC Growth

New Insights on Penetrium's Role in Combating TNBC Growth

Hyundai ADM Bio Unveils Promising Results for Penetrium

– Groundbreaking treatment strategy targets both primary and metastatic tumors.

Hyundai ADM Bio has announced significant findings related to its pioneering agent, Penetrium, which exhibited impressive anti-metastatic properties in recent preclinical studies involving triple-negative breast cancer (TNBC). This cutting-edge research aims to tackle the challenges presented by tumor pseudo-resistance, a common hurdle in cancer therapies.

Effectiveness of Penetrium in Preclinical Studies

Through research conducted by NodCure, a specialized preclinical contract research organization, insights emerged showing that paclitaxel, when used alone, only led to a mere 4.55% reduction in tumor size, while greatly enhancing metastasis by over 115%. In stark contrast, the combination of paclitaxel with Penetrium yielded a tumor size reduction of 36.22% and a significant metastasis decrease of 85.78%. These results underline the potential of Penetrium to enhance the efficacy of conventional chemotherapy.

Combating Therapy-Induced Barriers

The repeated administration of chemotherapy often leads to the hardening of the tumor's extracellular matrix (ECM), which diminishes the treatment's effectiveness. Penetrium takes a novel approach by softening the ECM barriers that have developed due to previous therapies, thereby restoring the critical pathways for anticancer drugs and immune cells to access the tumors effectively.

Understanding Pre-Metastatic Niches

Pre-metastatic niches play a critical role in the growth of metastatic tumors. These microenvironments in distant organs are modified through ECM remodeling, increased blood vessel formation, and immune suppression. By inhibiting the formation of these niches, Penetrium prevents metastatic cells from establishing footholds in new locations. This research marks a critical advancement, offering evidence that Penetrium can effectively address some significant limitations of established cancer treatments.

Additional Research Findings

In a separate study focusing on non-small cell lung cancer (NSCLC), the combination of Penetrium with bevacizumab resulted in an unprecedented 0% metastasis rate. Immunohistochemistry analysis revealed that only in this combination treatment did the levels of metastasis-promoting factors MMP-9 and VEGF see suppression, further validating Penetrium's intended mechanism of action.

Penetrium’s Unique Approach to Cancer Treatment

Triple-negative breast cancer is notoriously known for its aggressive nature and high metastatic potential. Current therapies often fall short in extending patient survival or overcoming the challenges posed by ECM-driven drug delivery failures. Penetrium's distinctive strategy focuses on the tumor's microenvironment, rather than just directly attacking cancer cells. By restoring essential drug delivery pathways and bolstering immune system responses, Penetrium presents a fresh perspective in cancer treatment.

Expert Insights on Penetrium

Soo-Jung Kim, who leads Drug Development at Hyundai ADM, highlighted the significance of these findings: "Penetrium offers a transformative approach to cancer treatment by neutralizing barriers that hinder drug access. This research can potentially reshape the narrative surrounding the treatability of metastatic cancers."

Future Directions for Hyundai ADM

Hyundai ADM is not merely stopping at these findings; the company is keenly focused on expanding Penetrium-based clinical strategies beyond breast cancer to include lung cancer treatments. In parallel, Hyundai Bioscience is pursuing applications for other cancers, including pancreatic, prostate, and bile duct types. Both entities actively seek global partnerships in licensing and co-development to advance their groundbreaking technologies and findings after the upcoming AACR 2025 conference.

Frequently Asked Questions

What is Penetrium?

Penetrium is a patented pseudo-resistance targeting agent developed by Hyundai ADM Bio, designed to enhance the efficacy of cancer treatments.

How does Penetrium work?

Penetrium works by softening the extracellular matrix around tumors, improving the delivery of anticancer drugs and immune cells.

What types of cancer is Penetrium targeting?

Currently, Penetrium is being studied for its effects on triple-negative breast cancer and non-small cell lung cancer, with plans to explore other cancers.

What results were found in the studies?

Studies indicated that Penetrium significantly reduced tumor size and metastasis compared to traditional therapies.

What future plans does Hyundai ADM have for Penetrium?

Hyundai ADM plans to expand clinical applications for Penetrium in various cancers and pursue global partnerships for further development.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 19

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading

Top 5 Most Recently Viewed Articles

Leidos' Autonomous Vessels Chart Bold Naval Waters

Updated Category News Views 49

Leidos' Autonomous Leap with the U.S. Navy Well, today it's all about Leidos, an outfit that's been showing its grit in the world of maritime autonomy. Their systems aren't just tinkering around anymore—they're slicing through the waves at RIMPAC, the Rim of the Pacific, and running alongside the USS Theodore Roosevelt Carrier Strike Group. That's big news in anyone's...

Continue Reading
89bio to Showcase Pegozafermin Trial Insights at Major Conference

Updated Category News Views 67

89bio Presents Key Findings from ENLIVEN Phase 2b Trial 89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to developing innovative treatments for liver and cardiometabolic diseases, has exciting news. The company will present new analyses from its Phase 2b ENLIVEN trial, which assesses the efficacy of pegozafermin in patients suffering from metabolic...

Continue Reading
New Insights on Penetrium's Role in Combating TNBC Growth

Updated Category News Views 487

Hyundai ADM Bio Unveils Promising Results for Penetrium – Groundbreaking treatment strategy targets both primary and metastatic tumors. Hyundai ADM Bio has announced significant findings related to its pioneering agent, Penetrium, which exhibited impressive anti-metastatic properties in recent preclinical studies involving triple-negative breast cancer (TNBC). This...

Continue Reading
Designer Brands Inc. Reveals Upcoming Earnings Call for Q1 2025

Updated Category News Views 178

Upcoming Earnings Release for Designer Brands Inc. Designer Brands Inc. (NYSE: DBI), a leading force in footwear and accessories, has announced an important date for shareholders and interested parties alike. The company is set to release its earnings for the first quarter of 2025 on June 10, 2025. This marks a significant event, as it gives insights into the company's...

Continue Reading
Harvard Bioscience, Inc. Reports Q1 2025 Financial Performance

Updated Category News Views 374

Strong Financial Insights from Harvard Bioscience Harvard Bioscience, Inc. (NASDAQ: HBIO) recently shared its financial results for the first quarter, showcasing a mixed performance influenced by various market factors. The company expressed confidence in its revenue management and highlighted new product developments that are energizing its business strategies. Revenue...

Continue Reading